Tumor necrosis factor-blocking therapies

Rheumatology: Sixth Edition

Volumn 1-2, Issue , 2015, Pages 492-510

  Taylor, Peter C ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84900433193     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-09138-1.00063-2     Document Type: Chapter

References (144)

1. Feldmann M, Brennan FM, Foxwell BM, et al. The role of TNF alpha and IL-1 in rheumatoid arthritis. Curr Dir Autoimmun 2001, 3:188-199.
2. Elliott MJ, Maini RN, Feldmann M, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 1994, 344:1125-1127.
3. Charles P, Elliott MJ, Davis D, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 1999, 163:1521-1528.
4. Lorenz HM, Antoni C, Valerius T, et al. In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis. Short term cellular and molecular effects. J Immunol 1996, 156:1646-1653.
5. Ulfgren AK, Andersson U, Engstrom M, et al. Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis. Arthritis Rheum 2000, 43:2391-2396.
6. Paleolog EM, Hunt M, Elliott MJ, et al. Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis. Arthritis Rheum 1996, 39:1082-1091.
7. Tak PP, Taylor PC, Breedveld FC, et al. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 1996, 39:1077-1081.
8. Taylor PC, Peters AM, Paleolog E, et al. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum 2000, 43:38-47.
9. Taylor PC, Peters AM, Glass DM, Maini RN Effects of treatment of rheumatoid arthritis patients with an antibody against tumour necrosis factor alpha on reticuloendothelial and intrapulmonary granulocyte traffic. Clin Sci (Lond) 1999, 97:85-89.
10. Paleolog EM, Young S, Stark AC, et al. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. Arthritis Rheum 1998, 4:1258-1265.
11. Taylor PC Serum vascular markers and vascular imaging in assessment of rheumatoid arthritis disease activity and response to therapy. Rheumatology (Oxford) 2005, 44:721-728.
12. Taylor PC, Steuer A, Gruber J, et al. Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis. Arthritis Rheum 2004, 50:1107-1116.
13. Taylor PC, Steuer A, Gruber J, et al. Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one-year-delayed addition of infliximab to ongoing MTX therapy in patients with erosive early rheumatoid arthritis. Arthritis Rheum 2006, 54:47-53.
14. Brennan FM, Browne KA, Green PA, et al. Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy. Br J Rheumatol 1997, 36:643-650.
15. Catrina AI, Lampa J, Ernestam S, et al. Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis. Rheumatology (Oxford) 2002, 41:484-489.
16. Ziolkowska M, Kurowska M, Radzikowska A, et al. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. Arthritis Rheum 2002, 46:1744-1753.
17. Smeets TJ, Kraan MC, van Loon ME, Tak PP Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum 2003, 48:2155-2162.
18. Catrina AI, Trollmo C, af Klint E, et al. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. Arthritis Rheum 2005, 52:61-72.
19. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010, 69:964-975.
20. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005, 52:3381-3390.
21. van Vollenhoven RF, Ernestam S, Geborek P, et al. When MTX fails in early rheumatoid arthritis, the addition of infliximab is more effective than the addition of sulfasalazine and hydroxychloroquine: 1-year results of the Swefot clinical trial. Lancet 2009, 374:459-466.
22. Moreland LW, O'Dell JR, Paulus HE, et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus MTX in early, aggressive rheumatoid arthritis. Arthritis Rheum 2012, 64:2824-2835.
23. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus MTX versus MTX alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous MTX treatment. Arthritis Rheum 2006, 54:26-37.
24. Van de Putte LB, Rau R, Breedveld FC, et al. Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis 2003, 62:1168-1177.
25. Van De Putte LB, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004, 63:508-516.
26. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant MTX: the ARMADA trial. Arthritis Rheum 2003, 48:35-45.
27. Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant MTX therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004, 50:1400-1411.
28. Weinblatt ME, Schiff MH, Ruderman EM, et al. Efficacy and safety of etanercept 50mg twice weekly in patients with rheumatoid arthritis who are suboptimal responders to etanercept 50mg once weekly. Arthritis Rheum 2008, 58:1921-1930.
29. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997, 337:141-147.
30. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein in patients with rheumatoid arthritis receiving MTX. N Engl J Med 1999, 340:253-259.
31. Kremer JM, Weinblatt ME, Bankhurst AD, et al. Etanercept added to background MTX therapy in patients with rheumatoid arthritis: continued observations. Arthritis Rheum 2003, 48:1493-1499.
32. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and MTX in patients with early rheumatoid arthritis. N Engl J Med 2000, 343:1586-1593.
33. Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus MTX in patients with early rheumatoid arthritis: two year radiographic and clinical outcomes. Arthritis Rheum 2002, 46:1443-1450.
34. van der Heijde D, Klareskog L, Rodriguez-Valverde V, et al. Comparison of etanercept and MTX, alone and combined, in the treatment of rheumatoid arthritis. Arthritis Rheum 2006, 54:1063-1074.
35. Emery P, Breedveld FC, Hall S, et al. Comparison of MTX monotherapy with a combination of MTX and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008, 372:375-382.
36. St.Clair E, Wagner C, Fasanmade A, et al. Relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis. Arthritis Rheum 2002, 46:1451-1459.
37. Edrees AF, Misra SN, Abdou NI Anti-tumor necrosis factor (TNF) therapy in rheumatoid arthritis: correlation of TNF-alpha serum level with clinical response and benefit from changing dose or frequency of infliximab infusions. Clin Exp Rheumatol 2005, 23:469-474.
38. Elliott MJ, Maini RN, Feldman M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum 1993, 36:1681-1690.
39. Elliott MJ, Maini RN, Feldman M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994, 344:1105-1110.
40. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly MTX in rheumatoid arthritis. Arthritis Rheum 1998, 41:1552-1563.
41. Lipsky PE, van der Heijde DMFM, St.Clair EW, et al. Infliximab and MTX in the treatment of rheumatoid arthritis. N Engl J Med 2000, 343:1594-1602. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
42. Smolen JS, Han C, Bala M, et al. Evidence of radiographic benefit of treatment with infliximab plus MTX in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 2005, 52:1020-1030. ATTRACT Study Group.
43. St.Clair EW, Van Der Heijde DM, Smolen JS, et al. Combination of infliximab and MTX therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004, 50:3432-3443. Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group.
44. Quinn MA, Conaghan PG, O'Connor PJ, et al. Very early treatment with infliximab in addition to MTX in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005, 52(Suppl):27-35.
45. van der Kooij SM, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, et al. Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent onset rheumatoid arthritis. Ann Rheum Dis 2009, 68:914-921.
46. van der Kooij SM, le Cessie S, Goekoop-Ruiterman YP, et al. Clinical and radiological efficacy of initial versus delayed treatment with infliximab plus MTX in patients with early rheumatoid arthritis. Ann Rheum Dis 2009, 68:1153-1158.
47. van der Kooij SM, de Vries-Bouwstra JK, Goekoop-Ruiterman YP, et al. Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset rheumatoid arthritis. Arthritis Rheum 2009, 61:4-12.
48. Taylor PC Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. Curr Opin Pharmacol 2010, 10:308-315.
49. Choy EH, Hazleman B, Smith M, et al. Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxford) 2002, 41:1133-1137.
50. Keystone E, Heijde D, Mason D, et al. Certolizumab pegol plus MTX is significantly more effective than placebo plus MTX in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008, 58:3319-3329.
51. Smolen JS, Landewé RB, Mease PJ, et al. Efficacy and safety of certolizumab pegol plus MTX in active rheumatoid arthritis: the RAPID 2 Study. Ann Rheum Dis 2009, 68:797-804.
52. Fleischmann R, Vencovsky J, van Vollenhoven R, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis 2009, 68:805-811.
53. Shealy D, Cai A, Staquet K, Baker A, et al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor alpha. MAbs 2010, 2.
54. Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in MTX-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before MTX as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 2009, 60:2272-2283.
55. Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to TNF-α given by monthly subcutaneous injections, in active rheumatoid arthritis despite MTX: the GO-FORWARD Study. Ann Rheum Dis 2009, 68:789-796.
56. Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009, 374:210-221.
57. Nawata M, Saito K, Nakayamada S, Tanaka Y Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission. Mod Rheumatol 2008, 18:460-464.
58. Kavanaugh A, Fleischmann RM, Emery P, et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus MTX or MTX alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis 2013, 72:64-71.
59. Smolen JS, Fleischmann R, Emery P, et al. In: The OPTIMA study of MTX and adalimumab: 78-week outcomes in early rheumatoid arthritis patients based on achieving a low DAS28 target after 26 weeks (abstract THU0243) 2011, EULAR, London.
60. Smolen JS, Nash P, Durez P, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomized controlled trial. Lancet 2013, 381:918-929.
61. Kavanaugh A, Tutuncu Z, Catalan-Sanchez T Update on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis. Curr Opin Rheumatol 2006, 18:347-353.
62. Braun J, Baraliakos X, Listing J, Sieper J Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005, 52:2447-2451.
63. van der Heijde D, Landewe R, Einstein S, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008, 58:1324-1331.
64. van der Heijde D, Landewe R, Baraliakos X, et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 2008, 58:3063-3070.
65. van der Heijde D, Salonen D, Weissman BN, et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther 2009, 11:R127.
66. Baraliakos X, Haibel H, Listing J, et al. Radiographic progression in ankylosing spondylitis results after up to 8 years of infliximab treatment. Arthritis Rheum 2011, 63(Suppl):S208.
67. Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009, 60:976-986.
68. Genovese MC, Mease PJ, Thomson GT, et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying anti-rheumatic drug therapy. J Rheumatol 2007, 34:1040-1050.
69. Langford CA Update on Wegener granulomatosis. Cleve Clin J Med 2005, 72:689-690.
70. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005, 352:351-361. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group.
71. Stone JH, Holbrook JT, Marriott MA, et al. Solid malignancies among patients in the ANCA-associated granulomatous vasculitis Etanercept Trial. Arthritis Rheum 2006, 54:1608-1618. for the ANCA-associated granulomatous vasculitis Etanercept Trial Research Group.
72. Cantini F, Niccoli L, Salvarani C, et al. Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum 2001, 44:2933-2935.
73. Hoffman GS, Cid MC, Weyand CM, et al. Phase II study of the safety and efficacy of infliximab in giant cell arteritis (GCA): 22 week interim analysis. Arthritis Rheum 2005, 52(Suppl):S271.
74. Salavani C, Manzini C, Paolazzi G, et al. Infliximab in the treatment of polymyalgia rheumatica: a double blind, randomized, placebo controlled study. Arthritis Rheum 2005, 52(Suppl):S676.
75. Sweiss NJ, Welsch MJ, Curran JJ, Ellman MH Tumor necrosis factor inhibition as a novel treatment for refractory sarcoidosis. Arthritis Rheum 2005, 53:788-791.
76. Doty JD, Mazur JE, Judson MA Treatment of sarcoidosis with infliximab. Chest 2005, 127:1064-1071.
77. Pritchard C, Nadarajah K Tumour necrosis factor alpha inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients. Ann Rheum Dis 2004, 63:318-320.
78. Baughman RP, Lower EE, Bradley DA, et al. Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest 2005, 128:1062-1067.
79. Utz JP, Limper AH, Kalra S, et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003, 124:177-185.
80. Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006, 174:732-733.
81. Adisen E, Oztas M, Gurer MA Treatment of idiopathic pyoderma gangrenosum with infliximab: induction dosing regimen or on-demand therapy?. Dermatology 2008, 2:163-165.
82. Melikoglu M, Fresko I, Mat C, et al. Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study. J Rheumatol 2005, 32:98-105.
83. Mariette X, Ravaud P, Steinfeld S, et al. Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS). Arthritis Rheum 2004, 50:1270-1276.
84. Sankar V, Brennan MT, Kok MR, et al. Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum 2004, 50:2240-2245.
85. Van Der Vaart H, Koeter GH, Postma DS, et al. First study of infliximab treatment in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005, 172:465-469.
86. Wenzel SE, Barnes PJ, Bleecker ER, et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med 2009, 179:549-558.
87. Holgate ST, Noonan M, Chanez P, et al. Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial. Eur Respir J 2011, 37:1352-1359.
88. Zein NN Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005, 42:315-322. Etanercept Study Group.
89. Viganò M, Degasperi E, Aghemo A, Lampertico P, Colombo M Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management. Expert Opin Biol Ther 2012, 12:193-207.
90. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000, 342:763-769.
91. Moreland LW, Cohen SB, Baumgartner SW, et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 2001, 28:1238-1244.
92. Wolfe F, Caplan L, Michaud K Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum 2006, 54:628-634.
93. Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005, 52:3403-3412.
94. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295:2275-2285.
95. Dixon WG, Symmons DP, Lunt M, et al. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 2007, 56:2896-2904.
96. Askling J, Dixon W The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis. Curr Opin Rheumatol 2008, 20:138-144.
97. Ehrenstein MR, Evans JG, Singh A, et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti TNF-alpha therapy. J Exp Med 2004, 200:277-285.
98. Westhovens R, Yocum D, Han J, et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum 2006, 54:1075-1086. START Study Group.
99. Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005, 52:3403-3412.
100. Curtis JR, Patkar N, Xie A, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor α antagonists. Arthritis Rheum 2007, 56:1125-1133.
101. Carmona L, Descalzo MA, Perez-Pampin E, et al. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis 2007, 66:880-885.
102. Bernatsky S, Hudson M, Suissa S Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology (Oxford) 2007, 46:1157-1160.
103. Salliot C, Gossec L, Ruyssen-Witrand A, et al. Infections during tumour necrosis factor-α blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology (Oxford) 2007, 46:327-334.
104. Bernatsky S, Habel Y, Rahme E Observational studies of infections in rheumatoid arthritis: a meta-analysis of tumor necrosis factor antagonists. J Rheumatol 2010, 37:928-931.
105. Dixon WG, Watson K, Lunt M, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006, 54:2368-2376.
106. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and MTX compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004, 363:675-681.
107. Schneeweiss S, Setoguchi S, Weinblatt ME, et al. Anti-tumor necrosis factor α therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 2007, 56:1754-1764.
108. Strangfeld A, Eveslage M, Schneider M, et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?. Ann Rheum Dis 2011, 70:1914-1920.
109. Genovese MC, Cohen S, Moreland L, et al. 20000223 Study Group. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with MTX. Arthritis Rheum 2004, 50:1412-1419.
110. Weinblatt M, Combe B, Covucci A, et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum 2006, 54:2807-2816.
111. Giles JT, Bathon JM Serious infections associated with anticytokine therapies in the rheumatic diseases. J Intensive Care Med 2004, 19:320-334.
112. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005, 52:1766-1772. BIOBADASER Group.
113. Gomez-Reino JJ, Carmona L, Angel Descalzo M, Biobadaser G Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007, 57:756-761.
114. Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010, 69:522-528.
115. Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009, 60:1884-1994.
116. Furst DE, Cush J, Kaufmann S, et al. Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid arthritis in immunosuppressive trials or being treated with biological agents. Ann Rheum Dis 2002, 61(Suppl 2):ii62-ii63.
117. Hsia EC, Schluger N, Cush JJ, et al. Interferon-gamma release assay versus tuberculin skin test prior to treatment with golimumab, an human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Arthritis Rheum 2012, 64:2068-2077.
118. Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009, 301:737-744.
119. Askling J, Baecklund E, Granath F, et al. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheumatic Dis 2009, 68:648-653.
120. Wolfe F, Michaud K The effect of MTX and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 2007, 56:1433-1439.
121. Mariette X, Matucci-Cerenic M, Pavelka K, et al. Malignancies associated with TNF inhibitors in registries and prospective observational studies: a systematic review and metaanalysis. Ann Rheum Dis 2011, 70:1895-1904.
122. Askling J, Baecklund E, Granath F, et al. Anti-TNF therapy in RA and risk of malignant lymphomas. Relative risks and time-trends in the Swedish Biologics Register. Ann Rheum Dis 2009, 68:648-653.
123. Wolfe F, Michaud K Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007, 56:2886-2895.
124. Setoguchi S, Solomon DH, Weinblatt ME, et al. Tumor necrosis factor α antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum 2006, 54:2757-2764.
125. Askling J, Fored CM, Geborek P, et al. Swedish registers to examine drug safety and clinical issues in RA. Ann Rheum Dis 2006, 65:707-712.
126. Bartelds GM, Krieckaert GLM, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011, 305:1460-1468.
127. De Bant M, Sibilia J, Le Loet X, et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 2005, 7:R545-R551.
128. Shin IS, Baer AN, Kwon HJ, et al. Guillain-Barré and Miller Fisher syndromes occurring with tumor necrosis factor α antagonist therapy. Arthritis Rheum 2006, 54:1429-1434.
129. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999, 53:457-465. Lenercept Multiple Sclerosis Study Group.
130. Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003, 107:3133-3140.
131. Cole J, Busti A, Kazi S The incidence of new onset congestive heart failure and heart failure exacerbation in Veterans Affairs patients receiving tumor necrosis factor α antagonists. Rheumatol Int 2007, 27:369-373.
132. Verstappen SM, King Y, Watson KD, et al. Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011, 70:823-826.
133. Lichtenstein G, Cohen RD, Feagan BG, et al. Safety of Infliximab in Crohn's disease: data from the 5000 patient TREAT registry. Gastroenterology 2004, 126:A54.
134. Harrison MJ, Dixon WG, Watson KD, et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2009, 68:209-215. British Society for Rheumatology Biologics Register Control Centre Consortium; BSRBR.
135. Franchimont D, Roland S, Gustot T, et al. Impact of infliximab on serum leptin levels in patients with Crohn's disease. J Clin Endocrinol Metab 2005, 90:3510-3516.
136. Bennett AN, Wong M, Zain A, et al. Adalimumab-induced asthma. Rheumatology 2005, 44:1199-1200.
137. Ganeshan A, Quen L, Smith D Occurrence of vesicocolic fistula with a use of etanercept: a cautionary tale. J Clin Rheumatol 2005, 11:290-291.
138. Deng A, Harvey V, Sina B, et al. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors. Arch Dermatol 2006, 142:198-202.
139. Corsi F, Previde P, Colombo F, et al. Two cases of intestinal perforation in patients on anti-rheumatic treatment with etanercept. Clin Exp Rheumatol 2006, 24:113.
140. Phillips K, Weinblatt M Granulomatous lung disease occurring during etanercept treatment. Arthritis Rheum 2005, 53:618-620.
141. Richez C, Blanco P, Lagueny A, et al. Neuropathy resembling CIDP in patients receiving tumor necrosis factor-alpha blockers. Neurology 2005, 64:1468-1470.
142. Stokes MB, Foster K, Markowitz GS, et al. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant 2005, 20:1400-1406.
143. Mor A, Bingham C, Barisoni L, et al. Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. J Rheumatol 2005, 32:740-743.
144. Montagna GL, Malesci D, Buono R, Valentini G Asthenoazoospermia in patients receiving anti-tumour necrosis factor-α agents. Ann Rheum Dis 2005, 64:1667.